Literature DB >> 16126618

Toxicokinetics and hydrolysis of artelinate and artesunate in malaria-infected rats.

Qigui Li1, Lisa H Xie, Yuanzheng Si, Elaine Wong, Ravi Upadhyay, Danielle Yanez, Peter J Weina.   

Abstract

Comparative toxicokinetic (TK) and hydrolysis studies of intravenously administered two new antimalarial agents, artelinate (AL) and artesunate (AS), were performed in malaria-infected rats using three daily equimolar doses (96 micromoles/kg). The TK evaluation was related to select one drug for severe malaria treatment in U.S. Army. Drug concentration of AS with daily dose of 36.7 mg/kg was one-third less on day 3 than on day 1, which resembled its active metabolite, dihydroartemisinin (DHA), suggesting an autoinduction of hepatic drug-metabolizing enzymes for AS. The results were similar to other artemisinin drugs, but not for AL. TK parameters of AL were very comparable from day 1 to day 3 at same AS molecular dose at 40.6 mg/kg. AS is the prodrug of DHA with the DHA/AS ratio of 5.26 compared to the ratio of 0.01 for DHA/AL. Other TK parameters revealed that the total AUC1-3 days (84.4 microg.h ml-1) of AL was fivefold higher than that of AS (15.7 microg.h ml-1 of AS plus DHA). The elimination half-life of AL (7.1 h) was much longer than that of AS (0.36 h) or DHA (0.72 h). The remarkable alteration of the TK shape of AL may be caused by poor conversion rates to DHA and an enterohepatic circulation, which is confirmed by the present TK and tissue distribution studies. Compared to AS, higher drug exposure levels and longer exposure time of AL in the rat blood may be the cause of its increased toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126618     DOI: 10.1080/10915810591007201

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  7 in total

1.  Single-dose pharmacokinetic interaction between artesunate and amodiaquine: assembling the clues for the purported interaction.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2008-08-08       Impact factor: 2.953

2.  Possible mechanisms of the hypoglycaemic effect of artesunate: Gender implication.

Authors:  Abdullateef Isiaka Alagbonsi; Toyin Mohammad Salman; Sheu Oluwadare Sulaiman; Kafayat Anike Adedini; Susan Kebu
Journal:  Metabol Open       Date:  2021-03-17

3.  Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinediamines administered in single and multiple doses in rats.

Authors:  Qigui Li; Michael P Kozar; Todd W Shearer; Lisa H Xie; Ai J Lin; Kirsten S Smith; Yuanzheng Si; Lalaine Anova; Jing Zhang; Wilbur K Milhous; Donald R Skillman
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

Review 4.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Superior Pyronaridine Single-Dose Pharmacodynamics Compared to Artesunate, Chloroquine, and Amodiaquine in a Murine Malaria Luciferase Model.

Authors:  Winter A Okoth; Elijah J Dukes; David J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

6.  Comparative pharmacokinetics and pharmacodynamics of intravenous artelinate versus artesunate in uncomplicated Plasmodium coatneyi-infected rhesus monkey model.

Authors:  Paktiya Teja-Isavadharm; Duangsuda Siriyanonda; Maneerat Rasameesoraj; Amporn Limsalakpeth; Nitima Chanarat; Natthasorn Komcharoen; Peter J Weina; David L Saunders; Montip Gettayacamin; R Scott Miller
Journal:  Malar J       Date:  2016-09-06       Impact factor: 2.979

Review 7.  Artemisinins: their growing importance in medicine.

Authors:  Sanjeev Krishna; Leyla Bustamante; Richard K Haynes; Henry M Staines
Journal:  Trends Pharmacol Sci       Date:  2008-08-25       Impact factor: 14.819

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.